



## CYP2C19基因多态性对奥美拉唑药动力学影响的系统评价

王璵珏<sup>1</sup>,唐惠林<sup>2</sup>,荆珊<sup>1</sup>,张华<sup>1</sup>,徐涛<sup>1</sup>,王豪<sup>1</sup>,刘开彦<sup>1</sup>,刘玉兰<sup>1\*</sup>

1. 北京大学人民医院科研处; 北京 100044; 2. 北京大学第三医院药剂科; 北京 100191

WANG Li-jue<sup>1</sup>, TANG Hui-lin<sup>2</sup>, JING Shan<sup>1</sup>, ZHANG Hua<sup>1</sup>, XU Tao<sup>1</sup>, WANG Hao<sup>1</sup>, LIU Kai-yan<sup>1</sup>, LIU Yu-lan<sup>1\*</sup>

1 Peking University People's Hospital, Science and Research Department, Beijing 100044, China, 2 Peking University Third Hospital, Department of Pharmacy, Beijing 100191, China

- [摘要](#)
- [参考文献](#)
- [相关文章](#)

[Download: PDF \(1742KB\)](#) | [HTML \(1KB\)](#) | [Export: BibTeX or EndNote \(RIS\)](#) | [Supporting Info](#)

**摘要** 目的 系统评价CYP2C19基因多态性对奥美拉唑药物代谢动力学的影响。方法 计算机检索截止至2012年2月的Cochrane、PubMed、Embase、CNKI等数据库,收集有关CYP2C19基因多态性对奥美拉唑药动力学影响的研究。用RevMan5.1软件对符合纳入标准的研究进行Meta分析。结果 共纳入12篇回顾性研究。其中英文8篇,中文4篇。Meta分析结果表明,CYP2C19基因多态性显著影响 $\rho_{\max}$ 、AUC、 $t_{1/2}$ 和 $CL/F$ 。PM基因型组的 $\rho_{\max}$ 、AUC和 $t_{1/2}$ 的值均大于HEM基因型组,且HEM基因型组均显著大于EM基因型组;基因型为EM人群的 $CL/F$ 显著大于HEM基因型组,HEM人群的 $CL/F$ 也显著大于EM基因型组。结论 CYP2C19基因多态性显著影响奥美拉唑的体内代谢,但其代谢还受多种其他因素影响,尚需高质量大样本量的前瞻性研究来证实。

**关键词:** 奥美拉唑 细胞色素P450C19 基因多态性

**Abstract:** Objective To evaluate the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics. METHODS Cochrane library, PubMed, Embase and CNKI databases were searched for trials investigating the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics reported before February 2012. Meta-analysis was performed by RevMan 5.1 software. RESULTS Twelve retrospective studies, eight in English and four in Chinese, were included. Meta-analysis showed that CYP2C19 polymorphism significantly influenced the  $\rho_{\max}$ , AUC,  $t_{1/2}$  and  $CL/F$ . The  $\rho_{\max}$ , AUC,  $t_{1/2}$  and  $CL/F$  in PM genotype group were higher than those in HEM group, and those in HEM group were significantly higher than in EM group. And the  $CL/F$  in EM group was significantly higher than that in HEM group followed by that in PM group. CONCLUSION CYP2C19 genetic polymorphism affects omeprazole exposure significantly, but there are still other influencing factors. Large prospective studies are needed.

**Keywords:** omeprazole, CYP2C19, genetic polymorphism

收稿日期: 2012-04-30;

基金资助:

广东省部产学研合作引导项目(2010B090400081); 佛山市高明区科技三项费用项目(201015)

通讯作者 刘玉兰,女,博士,教授,博士生导师 研究方向: 消化系统疾病的临床工作与基础研究 Tel/Fax: 88325531 E-mail: liuyulan@pkuph.edu.cn CYP2C19基因多态性对奥美拉唑药动力学影响的系统评价 王璵珏<sup>1</sup> Email: liuyulan@pkuph.edu.cn

作者简介: 王璵珏,女,硕士,药师 研究方向: 药物临床试验管理及临床药学 通讯作者: 刘玉兰,女,博士,教授,博士生导师 研究方向: 消化系统疾病的临床工作与基础研究 Tel/Fax: 88325531 E-mail: liuyulan@pkuph.edu.cn

引用本文:

王璵珏, 唐惠林, 荆珊等. CYP2C19基因多态性对奥美拉唑药动力学影响的系统评价[J] 中国药学期刊, 2013, V48(5): 374-379

WANG Li-Jue-, TANG Hui-Lin-, JING Shan- etc. Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole[J] Chinese Pharmaceutical Journal, 2013, V48(5): 374-379

[1] ZHOU X Q, DUAN L F, ZHANG Y, et al. Advance of CYP2C19 polymorphism on clinical efficacy of omeprazole. *Chin J Drug Applica Monit* (中国药

### Service

- ▶ [把本文推荐给朋友](#)
- ▶ [加入我的书架](#)
- ▶ [加入引用管理器](#)
- ▶ [Email Alert](#)
- ▶ [RSS](#)

### 作者相关文章

- ▶ [王璵珏](#)
- ▶ [唐惠林](#)
- ▶ [荆珊](#)
- ▶ [张华](#)
- ▶ [徐涛](#)
- ▶ [王豪](#)
- ▶ [刘开彦](#)
- ▶ [刘玉兰\\*](#)

- [2] PENG R G,WANG Q. Drug interactions between omeprazole and CYP2C19 genetic polymorphism. *J Luzhou Med Coll* (泸州医学院学报) ,2010,33(6): 718-720.
- [3] CHOWBAY B,LI H,DAVID M,*et al.* Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. *Br J Clin Pharmacol*,2005,60(2): 159-171. [crossref](#)
- [4] HUNFELD N G,MATHOT R A,TOUW D J,*et al.* Effect of CYP2C19\*2 and \*17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. *Br J Clin Pharmacol*,2008,65(5):752-760. [crossref](#)
- [5] YASUI-FURUKORI N,TAKENORIT,NAKAGAMI T,*et al.* Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. *British J Clinical Pharm*,2004,57 (4) :487-494. [crossref](#)
- [6] BALDWIN R M,OHLSSON S,PEDERSEN R S, *et al.*Increased omeprazole metabolism in carriers of the CYP2C19\*17 allele; A pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol*,2008,65(5):767-774. [crossref](#)
- [7] YIN O Q,TOMLINSON B,CHOW A H, *et al.* Omeprazole as a CYP2C19 marker in Chinese subjects: Assessment of its gene-doseeffect and intrasubjectvariability. *J Clin Pharmacol*,2004,44(6):582-589. [crossref](#)
- [8] SHIRAI N,FURUTA T,MORIYAMA Y, *et al.* Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. *Aliment Pharmacol Ther*,2001,15(12):1929-1937. [crossref](#)
- [9] KITA T,SAKAEDA T,AOYAMA N, *et al.*Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: Pharmacokinetic considerations. *Biol Pharm Bull*,2002,25(7):923-927. [crossref](#)
- [10] CHO J Y,YU K S,JANG I J, *et al.*Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. *Br J Clin Pharmacol*,2002,53(4):393-397. [crossref](#)
- [11] MA J J,LI J H,CAO X M,*et al.* The influence of CYP2C19 genotype on omeprazole pharmacokinetics and relative bioavailability. *Chin Pharmacol Bull* (中国药理学通报) ,2010,26(2): 258-262.
- [12] HU X P,XU J M,HU Y M, *et al.* The influence of CYP2C19 genotype on omeprazole pharmacokinetics and relative bioavailability. *Chin Pharmacol Bull* (中国药理学通报) ,2005,21(10): 1210-1213.
- [13] FU L Q,HUANG F,WU D Z,*et al.* Pharmacokinetic comparison of omeprazole and its metabolites between Chinese CYP2C19 Ems and PMs subjects. *Chin Pharm J* (中国药理学杂志) ,2004,39(8): 614-616.
- [14] HU Y M,XU J M. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of rebepazole and omeprazole in Chinese subjects . Hefei: Anhui Medical University (安徽医科大学) ,2005.
- [15] YANG Y X,LEWID J D,EPSTEIN S,*et al.* Long-term proton pumpinhibitor therapy and risk of hip fracture. *JAMA*,2006,296(24): 2947-2953.
- [16] WANG L J,TANG H L,DUAN J L. Influence of CYP2C19 genetic polymorphisms on voriconazole pharmacokinetics: A systematic review. *Chin J Clin Pharmacol* (临床药理学杂志) ,2011,27(8):607-611.
- [17] BALDWIN R M,OHLSSON S,PEDERSEN R S,*et al.* Increased omeprazole metabolism in carriers of the CYP2C19\*17 allele; A pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol*,2008,65(5):767-774. [crossref](#)
- [18] HUNFELD N G,MATHOT R A,TOUW D J,*et al.* Effect of CYP2C19\*2 and \*17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.*Br J Clin Pharmacol*, 2008,65(5):752-760.
- [19] FURUTA T,OHASHI K,KOSUGE K, *et al.* CYP2C19 Genotype status and effect of omeprazole on intragastric pH in humans. *Clin Pharmacol Ther*,1999,65 (5) :552-561. [crossref](#)
- [20] FURUTA T,SHIRAI N,SUGIMOTO M, *et al.* Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies . *Drug Metab Pharmacokinet*,2005,20 (3) :153-167. [crossref](#)
- [21] ISHIZAKI T,HORAI Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. *Aliment Pharmacol Ther*,1999,13(3):27-36.
- [1] 吴伟明,黄成珂,王军,戴歌心,王增寿\*.雷贝拉唑对大鼠体内稳态时氯吡格雷药动学的影响[J].中国药理学杂志,2013,48(4):289-292
- [2] 李永芳 杨梅 寇毅英.青海撒拉族人群CYP2C19基因多态性研究[J].中国药理学杂志,2012,47(7):539-542
- [3] 向倩 赵侠 周颖 崔一民.转运蛋白基因多态性与利培酮分布的相关性研究[J].中国药理学杂志,2012,47(6):454-457
- [4] 吴雄健 刘洪荣 谢军.奥美拉唑致急性痛风1例[J].中国药理学杂志,2012,47(4):315-
- [5] 张建萍,魏玉辉,张帆,武新安.肠道转运体在药物吸收中的作用[J].中国药理学杂志,2012,47(24):1970-1974
- [6] 夏东亚,左金梁,赵东祥,项勇,郭涛.中国汉族和蒙古族健康人药物代谢酶CYP3A4、CYP2C9、CYP2C19、CYP2D6基因多态性分析[J].中国药理学杂志,2012,47(24):2017-2021
- [7] 贾菲菲,谭志荣,周宏灏.寡肽转运蛋白PEPT2的遗传药理学研究进展[J].中国药理学杂志,2012,47(23):1869-1872
- [8] 张亚同,梁欣,赵楠,胡欣,李可欣,杨莉萍.老年患者VKORC1和CYP2C9基因多态性对华法林应用的影响及分析[J].中国药理学杂志,2012,47(23):1930-1933
- [9] 张海燕,方焕荣,杨协清,罗万慰,许联红,马守梅.血浆蛋白C基因多态性与华法林剂量相关性的研究[J].中国药理学杂志,2012,47(21):1741-1745

- [10] 陶兴茹, 邓婕, 宋洪涛.阿片类药物基因多态性研究进展[J]. 中国药学杂志, 2012,47(18): 1465-1468
- [11] 梁欣 乔彦 张亚同 胡欣 李可欣 杨莉萍.中国人群STX4基因多态性对华法林应用剂量的影响[J]. 中国药学杂志, 2011,46(9): 691-694
- [12] 刘恩荔 于海勇 赵辉 郑小楠 邵馨 刘茜.奥美拉唑对多潘立酮在大鼠体内药动学的影响[J]. 中国药学杂志, 2011,46(8): 619-622
- [13] 李茵 卢晓阳.基因多态性对器官移植后免疫抑制剂疗效影响的研究进展[J]. 中国药学杂志, 2011,46(8): 561-564
- [14] 李丹滢 彭婕 葛卫红 方芸 .CYP3A5基因多态性对临床药代动力学影响的研究进展[J]. 中国药学杂志, 2011,46(20): 1541-1545
- [15] 谢宇 宋洪涛 王庆华 杨顺良 谭建明.CYP3A5\*3和MDR1 G2677T/A基因多态性对肾移植患者环孢素A血药浓度及疗效的影响[J]. 中国药学杂志, 2011,46(20): 1591-1596